Immuno-Oncology

The rapidly changing field of immuno-oncology has begun to show great potential to revolutionize cancer treatment. To support the advancement of immuno-oncology diagnostics and treatment in the laboratory, ASCP is committed to developing education designed to:

1.
Enhance general knowledge and skills related to immuno-oncology among pathologists and laboratory professionals;
2.
Support the implementation and dissemination of best practices in immuno-oncology testing, treatment options, and communication in multidisciplinary teams to improve quality of care; and
3.
Increase awareness of new developments in the rapidly changing field of immuno-oncology.
Interested in supporting
ASCP's Immuno-Oncology
Educational Strategy?

ASCP is committed to seeking funding to support the development of education mapped to its comprehensive immuno-oncology strategy. To discuss potential sponsorship opportunities, please contact grants@ascp.org.

Free Education Opportunities

An Overview of Immuno-Oncology

This case-based online course will provide an overview of immuno-oncology addressing: introduction to immune biomarkers, checkpoints, pathways (such as PD-1/PD-L1, PD-L2, and CTLA4), and their roles in cancer treatment; the current scope of immune-based cancer therapy and why it is important; how immuno-oncology affects the field of pathology, and why oncologists and patients are asking for immuno-oncology tests; an overview of currently available immuno-oncology therapies; and current efforts to identify other potential biomarkers of response to cancer immunotherapies, such as tumor mutational burden, microsatellite instability, and tumor-infiltrating lymphocytes. The activity is approved for 1.0 AMA PRA Category 1 Credit™, CMLE, or SAMs CME credit.

Funded by an independent educational grant from Bristol-Myers Squibb.

REGISTER NOW

Immune-Related Adverse Events Secondary to Checkpoint-Inhibitor Therapy

This case-based online course will discuss common immune-related adverse events (irAEs) in patients undergoing immunotherapy, addressing the following topics: irAEs onset and frequency; reporting of irAEs in pathology reports; coverage of hepatic, pancreatic, cutaneous, and cardiac irAEs and their management and outcomes; and detailed discussion of patterns of injury in the gut for gastrointestinal irAEs. The activity is approved for 1.0 AMA PRA Category 1 Credit™, CMLE, or SAMs CME credit.

Funded by an independent educational grant from Bristol-Myers Squibb.

REGISTER NOW

Immuno-Oncology: Next-Generation Sequencing and the New Biomarker Landscape

This case based, interactive online course will allow pathologists and laboratory professionals, as well as oncologists and other members of the multidisciplinary cancer care team, to gain key scientific knowledge and skills in utilizing biomarkers, particularly next-generation sequencing for identifying tumor mutation burden, for testing and selection of appropriate IO therapies, to provide patients with a personalized approach during each stage of their treatment regimens. The activity is approved for 1.5 AMA PRA Category 1 Credits™, CMLE, or SAMs CME credit.

Funded by an independent educational grant from Bristol-Myers Squibb.

REGISTER NOW

ASCP Scientific Updates

ASCP Scientific Updates are a quarterly series of 30-minute on-demand webcasts containing up-to-the-minute information on various therapeutic agents, disease states, and thresholds that impact immuno-oncology diagnostics in solid tumors and hematologic malignancies. Each activity is approved for 0.5 AMA PRA Category 1 Credits™, CMLE, or SAMs CME credit.

Funded by an independent educational grant from AstraZeneca.

  1. ASCP Scientific Update 1: Molecular Marker Testing Recommendations for Lung Cancer Treatment
  2. ASCP Scientific Update 2: Launching 6/30/18
  3. ASCP Scientific Update 3: Launching 9/30/18
  4. ASCP Scientific Update 4: Launching 12/31/18

*YouTube videos and Highlights are not eligible for CME credits.